2 results
Approved WMOCompleted
Primary objective:- To determine the clinical efficacy of multiple doses of 177Lu-DOTA-cG250 at MTD in patients with advanced renal cancer using RECIST criteriaSecondary objectives:- To determine the toxicity of the treatment as defined by NCI…
Approved WMORecruiting
This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed.